EMA's policy on pharmacovigilance: access to qualitative data is needed, pharmacovigilance data are not "trade secrets"

Joint response to the EMA consultation by the Cochrane AEMG, HAI Europe, ISDB and MiEF. “Protection of personal data” must not be used as a pretext to strengthen intellectual property over pharmacovigilance data.